Cargando…

Characteristics of patients with hematologic malignancies without seroconversion post-COVID-19 third vaccine dosing

OBJECTIVES: The objective of this study is to explore the characteristics of the subset of patients with hematologic malignancies (HMs) who had little to no change in SARS-CoV-2 spike antibody index value levels after a third mRNA vaccine dose (3V) and to compare the cohort of patients who did and d...

Descripción completa

Detalles Bibliográficos
Autores principales: Hallmeyer, Sigrun, Thompson, Michael A, Fitzpatrick, Veronica, Liao, Yunqi, Mullane, Michael P, Medlin, Stephen C, Copeland, Kenneth, Weese, James L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982360/
https://www.ncbi.nlm.nih.gov/pubmed/36873569
http://dx.doi.org/10.1093/biomethods/bpad002
_version_ 1784900313492226048
author Hallmeyer, Sigrun
Thompson, Michael A
Fitzpatrick, Veronica
Liao, Yunqi
Mullane, Michael P
Medlin, Stephen C
Copeland, Kenneth
Weese, James L
author_facet Hallmeyer, Sigrun
Thompson, Michael A
Fitzpatrick, Veronica
Liao, Yunqi
Mullane, Michael P
Medlin, Stephen C
Copeland, Kenneth
Weese, James L
author_sort Hallmeyer, Sigrun
collection PubMed
description OBJECTIVES: The objective of this study is to explore the characteristics of the subset of patients with hematologic malignancies (HMs) who had little to no change in SARS-CoV-2 spike antibody index value levels after a third mRNA vaccine dose (3V) and to compare the cohort of patients who did and did not seroconvert post-3V to get a better understanding of the demographics and potential drivers of serostatus. STUDY DESIGN: This retrospective cohort study analyzed SARS-CoV-2 spike IgG antibody index values pre and post the 3V data on 625 patients diagnosed with HM across a large Midwestern United States healthcare system between 31 October 2019 and 31 January 2022. METHODS: To assess the association between individual characteristics and seroconversion status, patients were placed into two groups based on IgG antibody status pre and post the 3V dose, (−/+) and (−/−). Odds ratios were used as measures of association for all categorical variables. Logistic regressions were used to measure the association between HM condition and seroconversion. RESULTS: HM diagnosis was significantly associated with seroconversion status (P = 0.0003) with patients non-Hodgkin lymphoma six times the odds of not seroconverting compared with multiple myeloma patients (P = 0.0010). Among the participants who were seronegative prior to 3V, 149 (55.6%) seroconverted after the 3V dose and 119 (44.4%) did not. CONCLUSION: This study focuses on an important subset of patients with HM who are not seroconverting after the COVID mRNA 3V. This gain in scientific knowledge is needed for clinicians to target and counsel these vulnerable patients.
format Online
Article
Text
id pubmed-9982360
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-99823602023-03-04 Characteristics of patients with hematologic malignancies without seroconversion post-COVID-19 third vaccine dosing Hallmeyer, Sigrun Thompson, Michael A Fitzpatrick, Veronica Liao, Yunqi Mullane, Michael P Medlin, Stephen C Copeland, Kenneth Weese, James L Biol Methods Protoc Special Collection: Covid19 Methods & Protocols OBJECTIVES: The objective of this study is to explore the characteristics of the subset of patients with hematologic malignancies (HMs) who had little to no change in SARS-CoV-2 spike antibody index value levels after a third mRNA vaccine dose (3V) and to compare the cohort of patients who did and did not seroconvert post-3V to get a better understanding of the demographics and potential drivers of serostatus. STUDY DESIGN: This retrospective cohort study analyzed SARS-CoV-2 spike IgG antibody index values pre and post the 3V data on 625 patients diagnosed with HM across a large Midwestern United States healthcare system between 31 October 2019 and 31 January 2022. METHODS: To assess the association between individual characteristics and seroconversion status, patients were placed into two groups based on IgG antibody status pre and post the 3V dose, (−/+) and (−/−). Odds ratios were used as measures of association for all categorical variables. Logistic regressions were used to measure the association between HM condition and seroconversion. RESULTS: HM diagnosis was significantly associated with seroconversion status (P = 0.0003) with patients non-Hodgkin lymphoma six times the odds of not seroconverting compared with multiple myeloma patients (P = 0.0010). Among the participants who were seronegative prior to 3V, 149 (55.6%) seroconverted after the 3V dose and 119 (44.4%) did not. CONCLUSION: This study focuses on an important subset of patients with HM who are not seroconverting after the COVID mRNA 3V. This gain in scientific knowledge is needed for clinicians to target and counsel these vulnerable patients. Oxford University Press 2023-02-14 /pmc/articles/PMC9982360/ /pubmed/36873569 http://dx.doi.org/10.1093/biomethods/bpad002 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Special Collection: Covid19 Methods & Protocols
Hallmeyer, Sigrun
Thompson, Michael A
Fitzpatrick, Veronica
Liao, Yunqi
Mullane, Michael P
Medlin, Stephen C
Copeland, Kenneth
Weese, James L
Characteristics of patients with hematologic malignancies without seroconversion post-COVID-19 third vaccine dosing
title Characteristics of patients with hematologic malignancies without seroconversion post-COVID-19 third vaccine dosing
title_full Characteristics of patients with hematologic malignancies without seroconversion post-COVID-19 third vaccine dosing
title_fullStr Characteristics of patients with hematologic malignancies without seroconversion post-COVID-19 third vaccine dosing
title_full_unstemmed Characteristics of patients with hematologic malignancies without seroconversion post-COVID-19 third vaccine dosing
title_short Characteristics of patients with hematologic malignancies without seroconversion post-COVID-19 third vaccine dosing
title_sort characteristics of patients with hematologic malignancies without seroconversion post-covid-19 third vaccine dosing
topic Special Collection: Covid19 Methods & Protocols
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982360/
https://www.ncbi.nlm.nih.gov/pubmed/36873569
http://dx.doi.org/10.1093/biomethods/bpad002
work_keys_str_mv AT hallmeyersigrun characteristicsofpatientswithhematologicmalignancieswithoutseroconversionpostcovid19thirdvaccinedosing
AT thompsonmichaela characteristicsofpatientswithhematologicmalignancieswithoutseroconversionpostcovid19thirdvaccinedosing
AT fitzpatrickveronica characteristicsofpatientswithhematologicmalignancieswithoutseroconversionpostcovid19thirdvaccinedosing
AT liaoyunqi characteristicsofpatientswithhematologicmalignancieswithoutseroconversionpostcovid19thirdvaccinedosing
AT mullanemichaelp characteristicsofpatientswithhematologicmalignancieswithoutseroconversionpostcovid19thirdvaccinedosing
AT medlinstephenc characteristicsofpatientswithhematologicmalignancieswithoutseroconversionpostcovid19thirdvaccinedosing
AT copelandkenneth characteristicsofpatientswithhematologicmalignancieswithoutseroconversionpostcovid19thirdvaccinedosing
AT weesejamesl characteristicsofpatientswithhematologicmalignancieswithoutseroconversionpostcovid19thirdvaccinedosing